Raffles Medical's Share-Price Weakness May Be Short-Lived -- Market Talk
Raffles Medical's Share-Price Weakness May Be Short-Lived -- Market Talk
0707 GMT - Raffles Medical's recent share-price weakness may be short-lived, RHB Research says. Shares of the company slipped 11% from their mid-October high amid concerns that the reduction in the number of tests that travelers need to undergo, as part of vaccinated travel lane requirements, may hurt testing-related earnings. Travelers now only need to be tested upon completing their quarantine rather than also on arrival. However, RHB believes the rise in patient loads at healthcare facilities in 2022 should boost earnings and long-term growth. It keeps a buy rating and S$1.65 target price. Shares are 2.9% lower at S$1.33. (yongchang.chin@wsj.com)
0707GMT-RHB Research表示，萊佛士醫療公司(Raffles Medical)最近的股價疲軟可能是短暫的。該公司股價從10月中旬的高點下滑11%，原因是人們擔心，作為接種疫苗出行通道要求的一部分，旅行者需要接受的檢查次數的減少可能會損害與檢測相關的收益。旅行者現在只需在完成隔離後進行檢測，而不是在抵達時進行檢測。然而，RHB認為，2022年醫療機構患者數量的增加應該會提振收益和長期增長。它保持買入評級和1.65新元的目標價。股價下跌2.9%，至1.33新元。(yongchang.chin@wsj.com)
譯文內容由第三人軟體翻譯。
